Well, yesterday starting really good with PFE finally getting some love and the sector on decent footing but it certainly did not end well. We are now at the recent lows with odds likely favoring breaking the lows and triggering another leg lower. In some ways this is fundamentally and sentiment driven. As I noted […]
Perimeter Medical Imaging AI Update – Thesis advancing to fruition
Perimeter Medical Imaging AI (PINK.v, PYNKF) is a Toronto-based company with U.S. headquarters in Dallas, Texas that is driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools. Giving physicians the ability to visualize microscopic tissue structures “real time” in the operating room has the potential to result in better long-term outcomes for patients […]
May 5th Biotech Update
I guess that is my bad for writing on a Tuesday when I usually do not write. The sector and market did not seem to like that at all, so my bad. In all seriousness, that was certainly not a good day but actually might be good. We now have a clear upside resistance level […]
May 4th Biotech Update
I usually do not have time to write on Tuesday but wanted to put out a quick note. In general, we are still in a decision area with the sector. We have broken the clear downtrend but are not out of the woods and have certainly not established a clear uptrend. In any case, I […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
